Targeted Oncology14d
Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Safety
Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 (Ra-223) for androgen receptor pathway inhibitor (ARPI)–naive metastatic ...
Targeted Oncology14d
Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Efficacy Data
Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...
snmjournals.org14d
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET
Journal of Nuclear Medicine February 2025, jnumed.124.268340; DOI: https://doi.org/10.2967/jnumed.124.268340 ...
Cancer Research UK4mon
Consent forms for SACT (Systemic Anti-Cancer Therapy)
We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...
Frontiers2y
Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
Background: Abiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently ...
Frontiers3y
Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of ...